News Releases

Date Title View
Toggle Summary Aerie Pharmaceuticals to Present at the Stifel 2018 Healthcare Conference
DURHAM, N.C. --(BUSINESS WIRE)--Nov. 7, 2018-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other
View HTML
Toggle Summary Aerie Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update
Conference Call and Webcast Today, November 6 th , at 5:00 p.m. ET DURHAM, N.C. --(BUSINESS WIRE)--Nov. 6, 2018-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment
View HTML
Toggle Summary Aerie Pharmaceuticals to Announce Third Quarter 2018 Financial Results and Host Conference Call on Tuesday, November 6, 2018
DURHAM, N.C. --(BUSINESS WIRE)--Oct. 30, 2018-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie or the Company), announced today that its third quarter 2018 financial results will be released after the market closes on Tuesday, November 6, 2018 . Following the release, the Company will host a live
View HTML
Toggle Summary Aerie Pharmaceuticals Establishes GMP PRINT® Production Facility in an Expanded Global Headquarters
The Company now occupies more than 60,000 sq. ft. of laboratory and office space at the Durham, North Carolina , facility DURHAM, N.C. --(BUSINESS WIRE)--Oct. 23, 2018-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and
View HTML
Toggle Summary Aerie Pharmaceuticals, Inc. Announces Drug Application for Regulatory Approval Accepted for Review in Europe
European Medicines Agency (EMA) will begin review of the Marketing Authorisation Application (MAA) for Rhokiinsa ® (netarsudil ophthalmic solution) 0.02%, currently marketed as Rhopressa ® in the United States DURHAM, N.C. --(BUSINESS WIRE)--Oct. 9, 2018-- Aerie Pharmaceuticals, Inc.
View HTML
Toggle Summary Aerie Pharmaceuticals to Present at the Cantor Fitzgerald 2018 Global Healthcare Conference
DURHAM, N.C. --(BUSINESS WIRE)--Sep. 25, 2018-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Appointment of Damien Monaghan, Quality Director
DURHAM, N.C. --(BUSINESS WIRE)--Sep. 24, 2018-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other
View HTML
Toggle Summary Aerie Pharmaceuticals to Present at Ophthalmology Futures Forums in Vienna, Austria
DURHAM, N.C. --(BUSINESS WIRE)--Sep. 13, 2018-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other
View HTML
Toggle Summary Aerie Pharmaceuticals Appoints David W. Gryska to the Company’s Board of Directors
DURHAM, N.C. --(BUSINESS WIRE)--Sep. 12, 2018-- Aerie Pharmaceuticals, Inc.  (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Appointment of Robert Finan as Director of Finance
DURHAM, N.C. --(BUSINESS WIRE)--Sep. 11, 2018-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other
View HTML